再入院削减政策后急诊与观察单元急性护理利用及出院后结局:美国医保受益者全国回顾性队列研究
该回顾性队列研究利用2008-16年美国医保索赔数据,纳入65岁以上因心衰、急性心肌梗死或肺炎住院的患者(住院分别为3 772 924、1 570 113、3 131 162次)。出院后30天总死亡率心衰8.7%、心梗7.3%、肺炎8.4%;风险校正死亡率心衰每年增加0.05%(95%CI 0.02%至0.08%),心梗每年降低0.06%(95%CI -0.09%至-0.04%),肺炎无显著变化。心衰未利用任何出院后急性护理者死亡率每年增加0.08%(95%CI 0.05%至0.12%),超过心衰总体年绝对增幅,而观察单元或急诊就诊者死亡率未增加。30天再入院率降低的同时,三种疾病观察单元停留和急诊就诊在出院后30天内及31-90天均增加,总体30天急性护理利用无显著变化。
要点
- 心衰出院后30天内未利用任何急性护理者,风险校正死亡率每年增加0.08%(95%CI 0.05%至0.12%),超过心衰总体年增幅0.05%。
- 心衰出院后接受观察单元或急诊护理而未再入院者,死亡率未增加。
- 心梗出院后30天风险校正死亡率每年降低0.06%(95%CI -0.09%至-0.04%),肺炎无显著变化。
- 30天再入院率降低的同时,心衰、心梗、肺炎的观察单元停留和急诊就诊在出院后30天内及31-90天均增加。
- 三种疾病总体30天急性护理利用无显著变化;心衰和肺炎30天总体急性护理利用显著降低,心梗未降低。
适用人群与场景
- 美国2008-16年医保索赔数据中65岁及以上因心衰、急性心肌梗死或肺炎住院的患者,这三种疾病纳入美国医院再入院削减计划。
研究设计与关键结果
- 回顾性队列研究,基于美国2008-16年医保索赔数据,纳入心衰住院3 772 924次、急性心肌梗死住院1 570 113次、肺炎住院3 131 162次。
- 出院后30天总死亡率:心衰8.7%、急性心肌梗死7.3%、肺炎8.4%。
- 风险校正死亡率年变化:心衰每年增加0.05%(95%CI 0.02%至0.08%),急性心肌梗死每年降低0.06%(95%CI -0.09%至-0.04%),肺炎无显著变化。
- 心衰患者中未利用任何出院后急性护理者,死亡率每年增加0.08%(95%CI 0.05%至0.12%),超过心衰总体年绝对增幅;观察单元或急诊就诊者死亡率未增加。
- 30天再入院率降低的同时,三种疾病的观察单元停留和急诊就诊在出院后30天内及31-90天均增加。
- 总体30天急性护理利用无显著变化;心衰和肺炎30天总体急性护理利用显著降低,急性心肌梗死未降低。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 心衰出院后30天内未利用任何急性护理者死亡率逐年上升,而接受急诊或观察单元护理者死亡率未增加。
- 30天再入院率降低期间,观察单元停留和急诊就诊增加,总体30天急性护理利用无显著变化。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine whether patients discharged after hospital admissions for conditions covered by national readmission programs who received care in emergency departments or observation units but were not readmitted within 30 days had an increased risk of death and to evaluate temporal trends in post-discharge acute care utilization in inpatient units, emergency departments, and observation units for these patients.
DESIGN: Retrospective cohort study.
SETTING: Medicare claims data for 2008-16 in the United States.
PARTICIPANTS: Patients aged 65 or older admitted to hospital with heart failure, acute myocardial infarction, or pneumonia-conditions included in the US Hospital Readmissions Reduction Program.
MAIN OUTCOME MEASURES: Post-discharge 30 day mortality according to patients' 30 day acute care utilization; acute care utilization in inpatient and observation units and the emergency department during the 30 day and 31-90 day post-discharge period.
RESULTS: 3 772 924 hospital admissions for heart failure, 1 570 113 for acute myocardial infarction, and 3 131 162 for pneumonia occurred. The overall post-discharge 30 day mortality was 8.7% for heart failure, 7.3% for acute myocardial infarction, and 8.4% for pneumonia. Risk adjusted mortality increased annually by 0.05% (95% confidence interval 0.02% to 0.08%) for heart failure, decreased by 0.06% (-0.09% to -0.04%) for acute myocardial infarction, and did not significantly change for pneumonia. Specifically, mortality increased for patients with heart failure who did not utilize any post-discharge acute care, increasing at a rate of 0.08% (0.05% to 0.12%) per year, exceeding the overall absolute annual increase in post-discharge mortality in heart failure, without an increase in mortality in observation units or the emergency department. Concurrent with a reduction in 30 day readmission rates, stays for observation and visits to the emergency department increased across all three conditions during and beyond the 30 day post-discharge period. Overall 30 day post-acute care utilization did not change significantly.
CONCLUSIONS: The only condition with increasing mortality through the study period was heart failure; the increase preceded the policy and was not present among patients who received emergency department or observation unit care without admission to hospital. During this period, the overall acute care utilization in the 30 days after discharge significantly decreased for heart failure and pneumonia, but not for acute myocardial infarction.
参考来源
- Khera R, Wang Y, Bernheim SM, et al. Post-discharge acute care and outcomes following readmission reduction initiatives: national retrospective cohort study of Medicare beneficiaries in the United States. BMJ. 2020. PMID: 31941686. doi:10.1136/bmj.l6831
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。